Nirsevimab is protective against RSV infections and coinfections, which suggests there is no replacement of RSV with other viruses post-nirsevimab administration.

COVID-19 was associated with more severe disease outcomes than influenza or RSV during the 2022 to 2023 season.

The FDA will review a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).

People still see COVID-19 as an ongoing public health threat, even though the pandemic officially ended in 2023.

Vitamin D supplementation during TB treatment improves patient symptoms, but does not accelerate the clearance of TB bacteria.

For patients with HPV16-positive CIN3, vaccination with a replication-incompetent Semliki Forest virus vaccine encoding HPV16 E6 and E7 is safe and shows clinical effectiveness.

Heat-related deaths are expected to climb throughout Europe this century due to climate change, according to study findings.